Watch Dr. Sherman discuss lenvatinib
2015年6月23日
Lenvatinib brings thyroid cancer patient hope
BY洛瑞贝克
休利安诺基旅行每次他来到MD安德森时间497英里thyroid cancer treatment. Then it's 497 miles back home to Broken Arrow, Okla. He's been making the trip for five years, sometimes twice a month.
"It's been tremendously worth it," says Hugh, a 70-year-old Marine Corps veteran who's benefited from, and perhaps even survived because of, lenvatinib. This new thyroid cancer drug was tested here and approved by the Food and Drug Administration (FDA) in February.
Like Hugh, the drug had a long journey, and each step was taken at MD Anderson.
几十年来的一个处理后的新希望
直到最近，患者的放射性碘难治性甲状腺癌只有一个治疗方案。并没有一半以上的工作。
他们的命运对这次转机在2006年。
"In 2006, we began testing a drug called E7080 and found that several tumor types responded," says大卫•香港医学博士, in Investigational Cancer Therapeutics. "The response was particularly remarkable in thyroid cancer patients."
Like Hugh, the drug had a long journey, and each step was taken at MD Anderson.
几十年来的一个处理后的新希望
直到最近，患者的放射性碘难治性甲状腺癌只有一个治疗方案。并没有一半以上的工作。
他们的命运对这次转机在2006年。
"In 2006, we began testing a drug called E7080 and found that several tumor types responded," says大卫•香港医学博士, in Investigational Cancer Therapeutics. "The response was particularly remarkable in thyroid cancer patients."
Quick progression from promising to proven
Hong说的关于MD安德森的唯一一件事就是我们要利用这样的发现能力。
“当我们看到一些有前途的I期临床试验，MD安德森有专家和患者快速测试它在更大的II期临床试验，看是否可以帮助更多的患者，”他说。
"The response continued to be very impressive in the Phase II trial, so we were able to move it into an even larger Phase III trial, which is the final stage of testing," says玛丽亚Cabanillas，医学博士在内分泌肿瘤和荷尔蒙失调（ENHD），谁跑的II期临床试验。
一个谁从这种药物在III期临床试验中受益患者为休，谁在2010年来到MD安德森，并纳入试验于2012年。
Hugh admits the once-a-day pill took a toll on his digestion. But after three months, scans showed his cancer had shrunk.
“这是一个强烈的药物，并有副作用，需要仔细监测，”说ENHD的Mouhammed Amir Habra, M.D.，谁领导的III期临床试验的MD安德森的部分。HABRA能够减少休的用量，以帮助减少肚子的问题。
“在MD安德森接受治疗的另一个好处是，我们在修改的剂量，因此药物的效果，同时专家们最大限度地减少副作用保持” HABRA说。
"Dr. Habra and his staff have been remarkable," Hugh says. "They have a thorough knowledge of the treatment and how to explain it. I'm very grateful for the overall care and concern I have received as a patient."
吗？现在，对未来充满希望
According to clinical trial results published in the New England Journal of Medicine, patients taking E7080, now called lenvatinib, went 18.3 months -- on average -- without their cancers progressing. This was 14.7 months longer than those who received a placebo treatment.
Hong说的关于MD安德森的唯一一件事就是我们要利用这样的发现能力。
“当我们看到一些有前途的I期临床试验，MD安德森有专家和患者快速测试它在更大的II期临床试验，看是否可以帮助更多的患者，”他说。
"The response continued to be very impressive in the Phase II trial, so we were able to move it into an even larger Phase III trial, which is the final stage of testing," says玛丽亚Cabanillas，医学博士在内分泌肿瘤和荷尔蒙失调（ENHD），谁跑的II期临床试验。
一个谁从这种药物在III期临床试验中受益患者为休，谁在2010年来到MD安德森，并纳入试验于2012年。
Hugh admits the once-a-day pill took a toll on his digestion. But after three months, scans showed his cancer had shrunk.
“这是一个强烈的药物，并有副作用，需要仔细监测，”说ENHD的Mouhammed Amir Habra, M.D.，谁领导的III期临床试验的MD安德森的部分。HABRA能够减少休的用量，以帮助减少肚子的问题。
“在MD安德森接受治疗的另一个好处是，我们在修改的剂量，因此药物的效果，同时专家们最大限度地减少副作用保持” HABRA说。
"Dr. Habra and his staff have been remarkable," Hugh says. "They have a thorough knowledge of the treatment and how to explain it. I'm very grateful for the overall care and concern I have received as a patient."
吗？现在，对未来充满希望
According to clinical trial results published in the New England Journal of Medicine, patients taking E7080, now called lenvatinib, went 18.3 months -- on average -- without their cancers progressing. This was 14.7 months longer than those who received a placebo treatment.
重要的是，谁服用该药的人65％回答。
"This is almost unprecedented for thyroid cancer patients with such advanced disease," Habra says.
Four patients had a complete response, meaning there were no signs of cancer following treatment, he adds.
“整体响应速度和完整的答复代表进一步研究的非常激动人心的领域，让我们看到了希望的可能是提供治愈的患者数量更多，”说史蒂芬·谢尔曼，医学博士, chair of Endocrine Neoplasia and Hormonal Disorders and associate vice provost for Clinical Research.
抢先体验新疗法
Now that the drug's approved, patients everywhere can benefit.
“但我们的病人得到机会的好处要早得多，因为我们测试新的药物，”洪说。
While the drug may continue its journey for other cancers, the FDA approval means Hugh will be able to get the drug closer to home and make fewer trips to MD Anderson.
“MD安德森是任何其他医院不同，所以这是值得每英里，”休，谁也为他的妻子的支持和家人的热情款待和朋友谁已经打开了自己的家园五年感激说。
“你收到MD安德森的护理比较好，而且它的所有人民和气氛，”休补充道。“每当我遇到一个与癌症，首先想到的我是，‘你应该是在MD安德森。’”
Watch Dr. Sherman discuss lenvatinib:
这个故事的一个更长的版本最初发表在Messenger中，MD安德森双月刊员工公布。
"This is almost unprecedented for thyroid cancer patients with such advanced disease," Habra says.
Four patients had a complete response, meaning there were no signs of cancer following treatment, he adds.
“整体响应速度和完整的答复代表进一步研究的非常激动人心的领域，让我们看到了希望的可能是提供治愈的患者数量更多，”说史蒂芬·谢尔曼，医学博士, chair of Endocrine Neoplasia and Hormonal Disorders and associate vice provost for Clinical Research.
抢先体验新疗法
Now that the drug's approved, patients everywhere can benefit.
“但我们的病人得到机会的好处要早得多，因为我们测试新的药物，”洪说。
While the drug may continue its journey for other cancers, the FDA approval means Hugh will be able to get the drug closer to home and make fewer trips to MD Anderson.
“MD安德森是任何其他医院不同，所以这是值得每英里，”休，谁也为他的妻子的支持和家人的热情款待和朋友谁已经打开了自己的家园五年感激说。
“你收到MD安德森的护理比较好，而且它的所有人民和气氛，”休补充道。“每当我遇到一个与癌症，首先想到的我是，‘你应该是在MD安德森。’”
Watch Dr. Sherman discuss lenvatinib:
这个故事的一个更长的版本最初发表在Messenger中，MD安德森双月刊员工公布。